List of Clindesse drug patents
Clindesse is owned by Padagis Us.
Clindesse contains Clindamycin Phosphate.
Clindesse has a total of 2 drug patents out of which 0 drug patents have expired.
Clindesse was authorised for market use on 30 November, 2004.
Clindesse is available in cream;vaginal dosage forms.
Clindesse can be used as method of treating bacterial vaginosis.
The generics of Clindesse are possible to be released after 02 December, 2026.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6899890 | PADAGIS US | Bioadhesive drug delivery system |
Apr, 2023
(2 months from now) | |
| US9789057 | PADAGIS US | Pharmaceutical delivery system |
Dec, 2026
(3 years from now) | |
Drugs and Companies using CLINDAMYCIN PHOSPHATE ingredient
Market Authorisation Date: 30 November, 2004
Treatment: Method of treating bacterial vaginosis
Dosage: CREAM;VAGINAL
CLINDESSE family patents
11
United States
5
China
4
Australia
3
Korea, Republic of
3
Brazil
3
Japan
3
Argentina
3
Canada
3
European Union
1
Malaysia
1
Italy
1
Mexico
1
Hungary
1
South Africa
1
Portugal
1
Russia
1
Peru
1
Singapore
1
EA
1
France
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic